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Vaginal progesterone has a potential beneﬁcial eﬀect in postponing of preterm labor by suppression of prostaglandins cascades.
Although diﬀerent studies evaluated the use of progesterone for preterm birth, the exact eﬀect of which on prolongation of preg-
nancy remains unclear. Seventy two women who underwent preterm labor were managed by magnesium sulfate. Then they were
randomly assigned to continue pregnancy either by applying vaginal progesterone (400mg) until delivery or without using any
drug. Gestational age mean at the time of delivery (P = 0.039) and postponing delivery mean time (P = 0.048) were signiﬁcantly
higher in progesterone group. Comparison of neonatal outcomes between two groups of patients showed meaningful beneﬁts of
progesterone in increasing of neonatal weight, reduction of low birth weight babies, and lowing neonate admitted in NICU.
1.Introduction
The frequency of preterm delivery contributes a relatively
small proportion of total births (5–11%) [1, 2], while it is
associated with excess of 70% of the total perinatal mortality
in developed countries, when excluding deaths related to
congenital anomalies [3, 4].
Moreover, preterm delivery prevention is well recognized
as a major strategy for immediate and long-term costs
reduction after discharge from the hospital and childhood
morbidity [5–7].
Because of multifactorial (social, behavioral, and bio-
logical) causes in preterm delivery, eﬀorts in prevention
measures have not been successful so far [8]. Furthermore,
occurrence of spontaneous preterm birth increases 12–22%
in recent reports [9, 10].
Therefore, various tocolytic agents have been used to
postpone preterm uterine contractions for at least 48 hours
which allow maximal eﬀect of antenatal steroid admin-
istration to assist in fetal lung maturation and maternal
transportation to a center with neonatal intensive care unit
(NICU) [11].
From early 1960s, progesterone as a tocolytic agent was
used for the preventing of preterm birth [12]; however,
relationship between progesterone withdrawal and the onset
of labor is a considerable debate [13, 14].
Progesterone can aﬀect preterm labor reducing contrac-
tility and inﬂammatory processes [15–19].
Although previous studies reported that serum level
of progesterone following its vaginal administration is
lower comparing to intramuscular administration, optimal
route of progesterone administration in women undergone
preterm labour is yet being considered. Moreover, there
are controversial documents about the beneﬁt of vagi-
nal progesterone on spontaneous preterm birth [20]. We
designed randomized clinical trial study for clariﬁcation of
the eﬀect of vaginal progesterone on spontaneous preterm
birth.
2. Methods
2.1.Patients. AfterapprovingtrialprotocolofstudyinEthics
and Research, Committee of Beheshti University of Medical2 ISRN Obstetrics and Gynecology
SciencesandregistrationofclinicaltrialinIranianregistryof
clinical trial (IRCT: Code no. 7291), composed of specialized
antenatal clinics caring for preterm labour, women were
enrolled in the study for a period of 3 years from 2007 to
2010.
An RCT study was carried out during a 3-year period,
from March 2007 through March 2010 on all singleton
pregnancies at ≥24 and <34 weeks complicated with
preterm labor attending labor ward in Mahdieh Tertiary
Care Hospital aﬃliated to Shahid Beheshti University of
Medical Sciences in Tehran, Iran. The aim was to assess
the eﬃcacy of maintenance vaginal suppository of cyclogest
therapy in patients with cervical length less than 15mm by
vaginal ultrasound that acute preterm labor was successfully
controlled by intravenous magnesium sulfate. The criteria
used for the diagnosis of acute preterm labor included
persistent uterine contractions (e.g., at least four every 20
minutes or eight every 60 minutes), cervical dilation of 1 to
3cm,eﬀacement exceeding 50 percent, a change in cervical
dilation, or eﬀacement detected by serial examinations
[21, 22]. Gestational age was assigned based on the last
menstrual period (LMP) if it was conﬁrmed by ultrasound
or ultrasound alone when LMP was unknown. Intrauterine
growth restriction (IUGR) was deﬁned as birth weight less
than the ﬁfth percentile [23].
Exclusion criteria were preterm premature rupture of
membranes, premature termination for obstetric indica-
tions and fetal anomaly, vaginal bleeding, polyhydramnios,
fetal anomalies, suspected chorioamnionitis or intrauterine
growth retardation (IUGR), and concomitant cardiovascular
disease of woman (e.g., preeclampsia, gestational or chronic
hypertension).
2.2. Procedures and Outcomes. All these patients after admis-
sion to the labor ward initially received intravenous magne-
sium sulfate, a 6gr loading dose followed by maintenance
dose of 2gr/hour, to stop uterine contractions. All patients
were given betamethasone (12mg) and repeated after 24
hours and intravenous ampicillin (2gr) every 6 hour until
the results of group B streptococci vaginal cultures were
received.
The patients were weaned from intravenous magnesium
sulfate after uterine contractions were stopped for 24 hours.
Alleligibleparticipantsgavewritteninformedconsentbefore
study entrance. The patients were assigned for maintenance
vaginal suppository of cyclogest 400mg every night or
without using any drug randomly which was continued
until labour or 37 weeks of gestation. Permuted blocks
were scheduled to be given a participant number randomly
corresponding to a speciﬁc treatment (either active or
no drug packs). During treatment procedure, all study
personnel and participants were blinded except statistician
who did not have any contact with study participants.
Weekly vaginal sonography to assessment of cervical
length was performed for all patients. Until time of delivery,
w o m e nw e r ef o l l o w e du pf o rp r i m a r yo u t c o m e sw h i c hw e r e
recorded such as duration of pregnancy, gestational age of
delivery, type of delivery, duration of stay in hospital, and
intrauterine fetal death. Moreover, neonatal death, neonatal
unit admission, and duration of neonatal unit care were
compared between two groups.
2.3. Statistical Analysis. Statistical analysis on collected data
was processed by SPSS software (Version 16.0). Wilcoxon
signed paired test was used for before-after analysis of
these dependent samples, and diﬀerences were considered
statistically signiﬁcant when the P value was <0.05. Student
t-test and occasionally the Mann-Whitney test were used for
comparison of continuous variables. Linear regression was
recruited if the association of two continuous variables was
analyzed. Calculation of P<0.05 and odds ratios (ORs)
with 95% conﬁdence intervals (CIs) were estimated as a
signiﬁcant diﬀerence.
3. Results
Because of withdrawal of consent or being not traceable after
moving out of study area, 38 women were lost to followup in
both groups.
Therefore, primary outcome of 72 patients and controls
was available for analysis. There was no signiﬁcant diﬀerence
in demographics and clinical characteristics of the groups
(Table1). Mean gestational ageat the time of delivery (36.2±
1.4v e r s u s3 4 .1 ± 1.5; P value = 0.039) and mean time of
postponing delivery (4.0 ± 1.5v e r s u s1 .4 ± 0.2; P value =
0.048) were signiﬁcantly higher in patients who used vaginal
progesterone (Table 2). However, the mean of cervical length
and dilatation were not changed comparing groups after
treatment. Necessity to Cesarean section was more probable
in control group (19 patients; 26.5%) rather than cases (16
patients; 22.2%), but this diﬀerence was not meaningful.
There was no record for adverse events which need medical
care comparing two groups.
Table 3 shows the neonatal outcomes comparison
between two groups of patients. None of the women was
reportedwithanintrauterinedeathinbothgroups.Neonatal
mean weight was 2950.6 ± 420.3 in progesterone group and
2628.0±385.1inno-druggroup(P value¡0.001).Onlyeight
babies fulﬁlled criteria of low birth weight, in contrast to 26
born in no-drug group (P<0.001). The number of neonates
admitted in NICU had signiﬁcant diﬀerence between groups
(8.3% versus 23.6%; P value < 0.001). However, the P
value for the formal test of correlation between the type
of treatment and neonatal death was not signiﬁcant (P =
0.082).
4. Discussion
Preterm birth remains a signiﬁcant cause of early neonatal
mortalityandspeciﬁcmorbidityassociatedwithprematurity
[17, 24].
Based on this study ﬁnding, vaginal progesterone may
increasethedemurtimeofdeliveryifsucheﬃcacyconﬁrmed
by further investigation vaginal progesterone can eliminate
risk of hospitalization in the ﬁrst year of life, learningISRN Obstetrics and Gynecology 3
Table 1: Comparison of demographic data between two groups of patients.
Parameters Progesterone group No-drug group P value
Mean age ± SD (years) 24.2 ±3.72 5 .4 ±2.90 . 4 1
Mean initial gestational age ± SD (years) 32.2 ±2.83 2 .7 ±2.60 . 8 9
Mean length of cervix ± SD (cm) 1.8 ±0.31 .7 ±0.40 . 7 0
Mean dilatation of cervix ± SD (cm) 1.5 ±0.21 .6 ±0.30 . 9 1
Table 2: Comparison of maternal outcomes between two groups of patients.
Parameters Progesterone group
(N = 72)
No-drug group
(N = 72) P value
Mean gestational age at delivery ± SD (year) 36.2 ±1.43 4 .1 ±1.5 0.039
Mean time of postponing delivery ± SD (week) 4.0 ±1.51 .4 ±0.2 0.048
Mean of cervical length and dilatation ± SD 1.8 ±0.31 .7 ±0.40 . 7 1
Mean of cervical length and dilatation ± SD 1.5 ±0.21 .6 ±0.30 . 9 2
Type of delivery (Cesarean/NVD) 16/56 19/53 0.058
Table 3: Comparison of neonatal outcomes between two groups of patients.
Parameters Progesterone group
(N = 72)
No-drug group
(N = 72) P value
Mean weight of neonate ± SD (Kg) 2950.6 ±420.3 2628.0 ±385.1 <0.001
Number of low birth weight (%) 8 (11.1) 26 (36.1) <0.001
Number of neonates admitted in NICU (%) 6 (8.3) 17 (23.6) <0.001
Number of neonatal deaths (%) 3 (4.2) 8 (11.1) 0.08
diﬃculties [25, 26], behavioral problems [27, 28], and
burden of economic consequences [5, 29].
There is this hypothesis, “suppression of uterine contrac-
tile activity [15, 16, 30] through inhibition of the calcium-
calmodulin-myosin light chain kinase system [16, 30, 31]i s
the main role of progesterone in continuation of pregnancy
[31–33].”
Moreover, negative eﬀect of progesterone on prostaglan-
din production and interaction at the fetoplacental unit may
be a probable mechanism for clogging preterm birth [15, 18,
19].
Although the results of this study were the result of
400mg vaginal progesterone gel use, with ethical limitation,
we aﬀord routine tocolytic therapy to both case and no-drug
groups. Moreover, the route of progesterone administration
may aﬀect pharmacokinetics and peak blood concentrations
time (3 to 8 hours for 100mg vaginal progesterone). The
potentiallackofdelayedlocalabsorptionandmarginalblood
peaklevelcanbeprovedbyhigh-concentrationuseofvaginal
gel.However,thereweresimilareﬀectsofbothintramuscular
and vaginal progesterone in several systematic reviews of
randomized controlled trials. Similarly to date, the optimal
dose of vaginal preparations (ranging from 90 to 400mg
daily) [20, 34] and optimal time to commence therapy (24 to
28 weeks of gestation) [20, 35, 36] vary considerably across
studies. Obviously, selection of proper dosage and timing for
this study was resultant of all previous lucrative studies.
There is more limited information available relating to
deﬁnitive health outcomesof vaginal progesterone in women
presenting with symptoms or signs of threatened preterm
labour; therefore, an ongoing trial (by Matrinez et al.)
assessing this role will contribute information in the future
as well as our studied parameters.
Although we observed signiﬁcant advantages of vaginal
progesterone for the remainder of pregnancy on gestational
age at the time of delivery and time of postponing delivery
of women with spontaneous preterm labour, this ﬁnding
may not be repeated in women with other risk factors like
short cervix, past history of spontaneous preterm birth, and
multiple pregnancies [37–39].
During followups, there was no report received from
women complaining from sideeﬀects of vaginal progesterone
(headache, nausea, breast tenderness, and coughing) [40]i n
consistence with previous 2-year followup report of Northen
et al. [41]; but long-term side eﬀects on mothers and infants
should be considered in further investigations [42, 43].
Based on this randomized clinical trials ﬁnding, applica-
tion of vaginal progesterone has advantages in both maternal
and neonatal indexes, while the exact mechanism remains
unclear.
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